© Springer Science+Business Media New York 2015Ashraf Khan, Ian O. Ellis, Andrew M. Hanby, Ediz F. Cosar, Emad A. Rakha and Dina Kandil (eds.)Precision Molecular Pathology of Breast CancerMolecular Pathology Library1010.1007/978-1-4939-2886-6_12 12. Molecular-Based Diagnostic, Prognostic and Predictive Tests in…
© Springer Science+Business Media New York 2015Ashraf Khan, Ian O. Ellis, Andrew M. Hanby, Ediz F. Cosar, Emad A. Rakha and Dina Kandil (eds.)Precision Molecular Pathology of Breast CancerMolecular Pathology Library1010.1007/978-1-4939-2886-6_4 4. Molecular Pathology of Precancerous Lesions of the…
7 Relation to life expectancy, functional dependence, and tolerance to stress Relation to life expectancy and tolerance to stress Relation to life expectancy and dependence Relation to survival; may indicate…
Study Patients Chemotherapy type Time of assessment Age Cognitive assessment Results Mayerhofer et al. [27] Patients with advanced ovarian cancer (n = 28) Paclitaxel/carboplatin Before CT, after cycle 3, and after CT…
AGO-OVAR [11] GOG [37] EORTC 55971 pCRS iCRS [36] CHORUS pCRS iCRS [15] Suboptimal > 1 cm 29.6 months 35.0 months 26 months 25 22.8–24.5 Gross optimal ≤ 1 cm 36.2 months 42.4 months 32…
© Springer International Publishing Switzerland 2016Gilles Freyer (ed.)Ovarian Cancer in Elderly Patients10.1007/978-3-319-23588-2_9 9. Biological Research: Current Directions Claire Falandry1 , M. Bonnefoy1, Gilles Freyer2 and E. Gilson3, 4 (1) Geriatrics Unit, CarMEN Laboratory, Lyon Sud University Hospital, Lyon University,…
Albuminemia <35 g/L Lymphopenia <1 G/L ADL score <6 IADL score <25 HADS score >14 The number of points is the sum of “yes” A vulnerable patient is defined as…
© Springer International Publishing Switzerland 2016Gilles Freyer (ed.)Ovarian Cancer in Elderly Patients10.1007/978-3-319-23588-2_8 8. How to Design Clinical Trials? Sandro Pignata1 , Sabrina Chiara Cecere1 and Rosa Tambaro1 (1) Dipartimento Uro-Ginecologico, Istituto Nazionale Tumori “Fondazione G Pascale” – IRCCS, Naples,…
Clinical trial Phase Treatment schema N Median age [range] Responses CR + PR or HR Median PFS Cannistra (2007) [6] II Bev monotherapy 44 59.5 [31–87] 16 % 4.4 months Burger (2007)…
HG serous LG serous Mucinous Endometrioid Clear cell Incidence 70 % <5 % 3 % 10 % 5–10 % Risk factors BRCA1/2 ? ? HNPCC HNPCC+/- Precursor lesions STIC…
